RAF1 and neoplasm: Consistent with this, treatment with sorafenib, a RAF/ERK inhibitor, significantly decreased tumor weight and expression of RAF1 and ZEB1, a downstream effector of the RAF/ERK pathway, in HHUA-SP-derived tumors but not non-SP-derived tumors (Figs. 4–6).